EPO and lymphoma: In a study by Büyükpamukçu, on 34 patients with a variety of malignancies including solid tumors and lymphoma, the use of recombinant human erythropoietin at dosage of 150 units/ kg/ dose, 3 days per week, for 8 weeks was associated with reducing the need for blood transfusion and increasing hemoglobin in the receiving group [28].